What Happened

Click Therapeutics received FDA 510(k) clearance for Motivista, the first digital therapeutic indicated for negative symptoms of schizophrenia. The therapy, a smartphone app used alongside antipsychotic medication, targets social withdrawal and lack of drive.

The approval follows a restructuring of Click's partnership with Boehringer Ingelheim in April, which gave Click full commercial control and included a $50M Series D investment.

Who Is Affected

The clearance directly impacts Click Therapeutics, which is now building a commercial team and field deployment strategy. The company's recent layoffs indicate a lean, focused approach.

Boehringer Ingelheim remains an investor but has stepped back from commercialization. Competitors like Pear Therapeutics have struggled, highlighting the market's challenges.

Market Impact

• Motivista is the first FDA-authorized treatment for negative schizophrenia symptoms, addressing a large unmet need.
• Click's state-by-state Medicaid coverage strategy will determine market access, as Medicaid covers a significant share of adults with schizophrenia.
• The $50M Series D from Boehringer provides capital for commercialization, but Click is going it alone without a pharma partner for launch.
• No pricing has been set, but out-of-pocket models are unlikely due to patient reliance on Medicaid.

What to Watch

Watch for state-level Medicaid coverage decisions, which will dictate where Click deploys field resources. The company's ability to secure coverage will be critical to revenue.

Also monitor Click's commercial team build-out and any additional partnerships for distribution or patient access. The success of Motivista could set a precedent for digital therapeutics targeting psychiatric conditions.

Related coverage

• FDA approves Lilly's Jaypirca as first noncovalent BTK inhibitor for first-line CLL/SLL
• Mirum Pharmaceuticals Wins FDA Approval for Atebrioz for Rare Bone Disorder FOP
• FDA Approves Zilurgisertib (Atebrioz) for FOP in Patients 12 and Older
• FDA Approves Eli Lilly's Once-Weekly Basal Insulin Onswik for Type 2 Diabetes